Literature DB >> 21165747

Clinical practice: the management of hyperammonemia.

Johannes Häberle1.   

Abstract

Hyperammonemia is a life-threatening condition which can affect patients at any age. Elevations of ammonia in plasma indicate its increased production and/or decreased detoxification. The hepatic urea cycle is the main pathway to detoxify ammonia; it can be defective due to an inherited enzyme deficiency or secondary to accumulated toxic metabolites or substrate depletion. Clinical signs and symptoms in hyperammonemia are unspecific but they are mostly neurological. Thus, in any unexplained change in consciousness or in any unexplained encephalopathy, hyperammonemia must be excluded as fast as possible. Any delay in recognition and start of treatment of hyperammonemia may have deleterious consequences for the patient. Treatment largely depends on the underlying cause but is, at least in pediatric patients, mainly aimed at establishing anabolism to avoid endogenous protein breakdown and amino acid imbalances. In addition, pharmacological treatment options exist to improve urea cycle function or to remove nitrogen, but their use depend on the underlying disorder. To improve the prognosis of acute hyperammonemia, an increased awareness of this condition is probably more needed than anything else. Likewise, the immediate start of appropriate therapy is of utmost importance. This review focuses on a better understanding of factors leading to ammonia elevations and on practical aspects related to diagnosis and treatment in order to improve clinical management of hyperammonemia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21165747     DOI: 10.1007/s00431-010-1369-2

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  63 in total

Review 1.  Hyperammonemic encephalopathy.

Authors:  Saul W Brusilow
Journal:  Medicine (Baltimore)       Date:  2002-05       Impact factor: 1.889

2.  Valproate-induced hyperammonemic encephalopathy in the presence of topiramate.

Authors:  H M Hamer; S Knake; U Schomburg; F Rosenow
Journal:  Neurology       Date:  2000-01-11       Impact factor: 9.910

3.  Neurological outcome of patients with ornithine carbamoyltransferase deficiency.

Authors:  P Nicolaides; D Liebsch; N Dale; J Leonard; R Surtees
Journal:  Arch Dis Child       Date:  2002-01       Impact factor: 3.791

4.  New insights in nutritional management and amino acid supplementation in urea cycle disorders.

Authors:  Fernando Scaglia
Journal:  Mol Genet Metab       Date:  2010-03-01       Impact factor: 4.797

5.  Emergency treatment of neonatal hyperammonaemic coma with mild systemic hypothermia.

Authors:  A Whitelaw; S Bridges; A Leaf; D Evans
Journal:  Lancet       Date:  2001-07-07       Impact factor: 79.321

6.  1H MRS identifies symptomatic and asymptomatic subjects with partial ornithine transcarbamylase deficiency.

Authors:  A L Gropman; S T Fricke; R R Seltzer; A Hailu; A Adeyemo; A Sawyer; J van Meter; W D Gaillard; R McCarter; M Tuchman; M Batshaw
Journal:  Mol Genet Metab       Date:  2008-07-26       Impact factor: 4.797

7.  Cross-sectional multicenter study of patients with urea cycle disorders in the United States.

Authors:  Mendel Tuchman; Brendan Lee; Uta Lichter-Konecki; Marshall L Summar; Marc Yudkoff; Stephen D Cederbaum; Douglas S Kerr; George A Diaz; Margaretta R Seashore; Hye-Seung Lee; Robert J McCarter; Jeffrey P Krischer; Mark L Batshaw
Journal:  Mol Genet Metab       Date:  2008-06-17       Impact factor: 4.797

8.  The biochemical and molecular spectrum of ornithine transcarbamylase deficiency.

Authors:  M Tuchman; H Morizono; B S Rajagopal; R J Plante; N M Allewell
Journal:  J Inherit Metab Dis       Date:  1998       Impact factor: 4.982

Review 9.  Ammonia toxicity and its prevention in inherited defects of the urea cycle.

Authors:  V Walker
Journal:  Diabetes Obes Metab       Date:  2009-06-16       Impact factor: 6.577

10.  Survival after treatment with phenylacetate and benzoate for urea-cycle disorders.

Authors:  Gregory M Enns; Susan A Berry; Gerard T Berry; William J Rhead; Saul W Brusilow; Ada Hamosh
Journal:  N Engl J Med       Date:  2007-05-31       Impact factor: 91.245

View more
  22 in total

1.  Organ Distribution of 13N Following Intravenous Injection of [13N]Ammonia into Portacaval-Shunted Rats.

Authors:  Nancy F Cruz; Gerald A Dienel; Patricia A Patrick; Arthur J L Cooper
Journal:  Neurochem Res       Date:  2016-11-08       Impact factor: 3.996

2.  Arginase I deficiency: severe infantile presentation with hyperammonemia: more common than reported?

Authors:  Shailly Jain-Ghai; Sandesh C Sreenath Nagamani; Susan Blaser; Komudi Siriwardena; Annette Feigenbaum
Journal:  Mol Genet Metab       Date:  2011-07-13       Impact factor: 4.797

3.  Features of Adult Hyperammonemia Not Due to Liver Failure in the ICU.

Authors:  Amra Sakusic; Moldovan Sabov; Amanda J McCambridge; Alejandro A Rabinstein; Tarun D Singh; Kumar Mukesh; Kianoush B Kashani; David Cook; Ognjen Gajic
Journal:  Crit Care Med       Date:  2018-09       Impact factor: 7.598

Review 4.  Efficacy and Safety of Leucine Supplementation in the Elderly.

Authors:  Michael S Borack; Elena Volpi
Journal:  J Nutr       Date:  2016-11-09       Impact factor: 4.798

Review 5.  Current pathogenetic aspects of hepatic encephalopathy and noncirrhotic hyperammonemic encephalopathy.

Authors:  Halina Cichoż-Lach; Agata Michalak
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

6.  Effects of potassium adsorption filters on the removal of ammonia from blood products.

Authors:  Hiroshi Fujita; Yoko Shiotani; Yuko Takada; Shigeko Nishimura
Journal:  Blood Transfus       Date:  2017-03-01       Impact factor: 3.443

7.  Primary carnitine deficiency and pivalic acid exposure causing encephalopathy and fatal cardiac events.

Authors:  Jan Rasmussen; Olav W Nielsen; Allan M Lund; Lars Køber; Høgni Djurhuus
Journal:  J Inherit Metab Dis       Date:  2012-05-08       Impact factor: 4.982

8.  Non-cirrhotic Extra-Hepatic Porto-Systemic Shunt Causing Adult-Onset Encephalopathy Treated with Endovascular Closure.

Authors:  Massimiliano Allegritti; Benedetta Enrico; Emanuela Basile; Lara de Vito; Antonino Morabito; Roberto Cirocchi; Michela Giustozzi; Giovanni Passalacqua
Journal:  Dig Dis Sci       Date:  2020-04       Impact factor: 3.199

9.  Ammonia promotes endothelial cell survival via the heme oxygenase-1-mediated release of carbon monoxide.

Authors:  Xiao-Ming Liu; Kelly J Peyton; William Durante
Journal:  Free Radic Biol Med       Date:  2016-11-17       Impact factor: 7.376

10.  NMR-based metabolomics of human cerebrospinal fluid identifies signature of brain death.

Authors:  Martha E García-Aguilera; Eduardo Rodríguez de San Miguel; Jocelyn Cruz-Pérez; Lucinda Aguirre-Cruz; Christian M Ramirez-Alfaro; Nuria Esturau-Escofet
Journal:  Metabolomics       Date:  2021-04-16       Impact factor: 4.290

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.